Shanghai Allist Pharmaceuticals Co. Ltd. A (SHG:688578) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)
Shanghai Allist Pharmaceuticals Co. Ltd. A (SHG:688578) has a market capitalization of $6.29 Billion (CN¥42.99 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #3103 globally and #439 in its home market, demonstrating a -0.87% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Allist Pharmaceuticals Co. Ltd. A's stock price CN¥95.53 by its total outstanding shares 450000000 (450.00 Million). Analyse cash flow conversion of Shanghai Allist Pharmaceuticals Co. Ltd. to see how efficiently the company converts income to cash.
Shanghai Allist Pharmaceuticals Co. Ltd. A Market Cap History: 2020 to 2026
Shanghai Allist Pharmaceuticals Co. Ltd. A's market capitalization history from 2020 to 2026. Data shows growth from $1.85 Billion to $6.29 Billion (18.47% CAGR).
Shanghai Allist Pharmaceuticals Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Allist Pharmaceuticals Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.33x
Shanghai Allist Pharmaceuticals Co. Ltd. A's market cap is 1.33 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.14x
Shanghai Allist Pharmaceuticals Co. Ltd. A's market cap is 3.14 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.85 Billion | $560.89K | -$310.52 Million | 3302.84x | N/A |
| 2021 | $1.96 Billion | $530.09 Million | $18.27 Million | 3.71x | 107.49x |
| 2022 | $1.28 Billion | $791.00 Million | $130.52 Million | 1.62x | 9.81x |
| 2023 | $2.71 Billion | $2.02 Billion | $644.17 Million | 1.34x | 4.21x |
| 2024 | $3.94 Billion | $3.56 Billion | $1.43 Billion | 1.11x | 2.76x |
| 2025 | $6.86 Billion | $5.17 Billion | $2.18 Billion | 1.33x | 3.14x |
Competitor Companies of 688578 by Market Capitalization
Companies near Shanghai Allist Pharmaceuticals Co. Ltd. A in the global market cap rankings as of May 7, 2026.
Key companies related to Shanghai Allist Pharmaceuticals Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $108.50 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $74.92 Billion USD.
- UCB SA (BR:UCB): Ranked #513 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #572 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.50 Billion | $427.65 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.92 Billion | $721.05 |
| #513 | UCB SA | BR:UCB | $51.74 Billion | €236.00 |
| #572 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Shanghai Allist Pharmaceuticals Co. Ltd. A Historical Marketcap From 2020 to 2026
Between 2020 and today, Shanghai Allist Pharmaceuticals Co. Ltd. A's market cap moved from $1.85 Billion to $ 6.29 Billion, with a yearly change of 18.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥6.29 Billion | -8.28% |
| 2025 | CN¥6.86 Billion | +73.87% |
| 2024 | CN¥3.94 Billion | +45.56% |
| 2023 | CN¥2.71 Billion | +111.69% |
| 2022 | CN¥1.28 Billion | -34.83% |
| 2021 | CN¥1.96 Billion | +6.04% |
| 2020 | CN¥1.85 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Shanghai Allist Pharmaceuticals Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.29 Billion USD |
| MoneyControl | $6.29 Billion USD |
| MarketWatch | $6.29 Billion USD |
| marketcap.company | $6.29 Billion USD |
| Reuters | $6.29 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China. Its lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), as well as for treating adult patients with locally advanced or metastatic NSCLC. The co… Read more